Cargando…

Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress

Internal tandem duplication of fms-like tyrosine kinase-3 (FLT3-ITD) is frequent (30 percent) in acute myeloid leukemia (AML), and is associated with short disease-free survival following chemotherapy. The serine threonine kinase Pim-1 is a pro-survival oncogene transcriptionally upregulated by FLT3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doshi, Kshama A., Trotta, Rossana, Natarajan, Karthika, Rassool, Feyruz V., Tron, Adriana E., Huszar, Dennis, Perrotti, Danilo, Baer, Maria R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217017/ https://www.ncbi.nlm.nih.gov/pubmed/27374090 http://dx.doi.org/10.18632/oncotarget.10209

Ejemplares similares

Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication
por: Scarpa, Mario, et al.
Publicado: (2021)

PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers
por: Dellomo, Anna J., et al.
Publicado: (2021)

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015)

Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication
por: Natarajan, Karthika, et al.
Publicado: (2013)

Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells
por: Liu, Xiao-Jian, et al.
Publicado: (2020)

Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
por: Burchert, Andreas
Publicado: (2021)

MicroRNA networks in FLT3-ITD acute myeloid leukemia
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
por: Haage, Tobias R., et al.
Publicado: (2023)

Cytoplasmic DROSHA and Non-canonical Mechanisms of MiR-155 Biogenesis in FLT3-ITD Acute Myeloid Leukemia
por: Nguyen, Le Xuan Truong, et al.
Publicado: (2021)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
por: Iannotta, R., et al.
Publicado: (2022)

Dissection of PIM serine/threonine kinases in FLT3-ITD–induced leukemogenesis reveals PIM1 as regulator of CXCL12–CXCR4-mediated homing and migration
por: Grundler, Rebekka, et al.
Publicado: (2009)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
por: Pillinger, Genevra, et al.
Publicado: (2015)

Feature genes predicting the FLT3/ITD mutation in acute myeloid leukemia
por: LI, CHENGLONG, et al.
Publicado: (2016)

Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia
por: Sies, Katharina, et al.
Publicado: (2019)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
por: Lee, Lauren Y., et al.
Publicado: (2021)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia
por: Cao, Tingyong, et al.
Publicado: (2019)

Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD(+) acute myeloid leukemia
por: Li, Dan, et al.
Publicado: (2020)

Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era
por: Choi, Sujin, et al.
Publicado: (2020)

Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia
por: Park, Jung Eun, et al.
Publicado: (2013)

The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2017)

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia
por: Naseem, Shano, et al.
Publicado: (2021)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD(+) acute myeloid leukemia cells
por: Liu, Yi, et al.
Publicado: (2021)

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)

Flt3-ITD mutations in a mouse model of radiation-induced acute myeloid leukaemia
por: Finnon, R, et al.
Publicado: (2012)

FLT3-ITDs Instruct a Myeloid Differentiation and Transformation Bias in Lymphomyeloid Multipotent Progenitors
por: Mead, Adam J., et al.
Publicado: (2013)

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2015)

An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia
por: Lopez, Sophie, et al.
Publicado: (2016)

Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia
por: Heydt, Q, et al.
Publicado: (2018)

Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD(+) acute myeloid leukemia
por: Ueno, Yoko, et al.
Publicado: (2019)

Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2019)

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
por: He, Bai‐Liang, et al.
Publicado: (2020)

Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3‐ITD‐driven acute myeloid leukemia
por: Lopez‐Reyes, Rosa G., et al.
Publicado: (2020)

FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation
por: Engen, Caroline, et al.
Publicado: (2021)

Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo
por: Spohr, Corinna, et al.
Publicado: (2021)

A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
por: Wang, Peihong, et al.
Publicado: (2021)

CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia
por: Karnan, Sivasundaram, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_icuuhf6cs1v8d5ub95q608ms5o